Conference
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
Authors
Matulonis UA; Oza AM; Secord AA; Roman LD; Blagden SP; Banerjee SN; Elkas JC; Nemunaitis JJ; Ghamande SA; Fleming GF
Volume
34
Pagination
pp. 5547-5547
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2016
DOI
10.1200/jco.2016.34.15_suppl.5547
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X